Emiel De Jaeghere
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent - Emiel.DeJaeghere@UGent.be
- ORCID iD
-
0000-0001-6314-6179
Show
Sort by
-
- Journal Article
- A1
- open access
Completion surgery after intensity-modulated arc therapy for locally advanced cervical cancer : long-term follow-up and update on surgical outcome and oncologic results of a unique tertiary care single-center retrospective cohort
-
2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial
(2022) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. In International Journal of Gynecological Cancer 32(Supplement 2). p.A187-A188 -
- Journal Article
- A1
- open access
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study
-
- Journal Article
- A1
- open access
Mental health and quality of life among patients with cancer during the SARS-CoV-2 pandemic : results from the longitudinal ONCOVID survey study
-
Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma
-
- Journal Article
- A1
- open access
Risk of thrombo-embolic events in ovarian cancer : does bevacizumab tilt the scale? A systematic review and meta-analysis
-
How are OCD patients and family members dealing with the waxing and waning pattern of the COVID-19 pandemic? Results of a longitudinal observational study
-
Splenic hematopoietic and stromal cells in cancer progression
-
Splenic 18F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer
-
Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead towards personalized treatment